RxDoctor Payments Data

Amanda Era

Adult Health · Annapolis, MDNPI 1649495250

Payments from drug & device makers

$1,088in general payments, 2019–2025

Across 42 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$422
  • Johnson & Johnson$242
  • Madrigal Pharmaceuticals$218
  • Ardelyx, Inc.$45
  • Takeda Pharmaceuticals U.S.A., Inc.$39
  • Pfizer$35
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$1,03495%
  • Education$545%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,088 in reported general payments places this provider in the 70th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$72,446
Medicare patients
560
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase28$51,313
TrulancePlecanatide33$40,129
Dexlansoprazole DrDexlansoprazole90$36,564
LinzessLinaclotide24$33,036
Mesalamine23$16,590
Pantoprazole Sodium400$7,028
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates118$6,972
Famotidine113$2,610
Lubiprostone13$2,538
Esomeprazole Magnesium59$2,162
Rabeprazole Sodium40$2,071
Omeprazole103$1,772
Cholestyramine LightCholestyramine12$1,547
Budesonide EcBudesonide11$1,384
Colestipol Hcl14$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$422$84,34952 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$34$40,12933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 542 adult health providers in Maryland.

Other adult health in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →